NCT07655739Completed
The Effects of Sleeve Gastrectomy on Fractalkine
Temporal Changes in Fractalkine (CX3CL1) Levels Following Sleeve Gastrectomy and Their Association With Weight Loss: A Prospective Study
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
Fractalkine (CX3CL1) is a unique chemokine involved in leukocyte adhesion, migration, and obesity-associated adipose tissue inflammation. Although bariatric surgery results in substantial weight loss and metabolic improvement, the temporal pattern of circulating CX3CL1 levels following laparoscopic sleeve gastrectomy (LSG) remains poorly understood. This study aimed to evaluate longitudinal changes in serum CX3CL1 levels after LSG and to investigate their association with postoperative weight loss.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 13 Jun 2026
- Start date
- 4 Sept 2025
- Primary completion date
- 4 Jan 2026
- Lead sponsor
- Mehmet Buğra Bozan
- Diseases
- Obesity
- NCT number
- NCT07655739
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 4 Sept 2025 to the primary completion date, 4 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- • Corticosteroid or immunosuppressive therapy
Other illness
- • Active infection or acute inflammatory condition
- • Autoimmune or chronic inflammatory disease
- • History of malignancy
- • Chronic liver or kidney disease
Other
- • Pregnancy or lactation
- • Major postoperative complications
- • Missing data or incomplete sampling
Who the study is looking for
- • Age ≥18 years
- • Elective laparoscopic sleeve gastrectomy
- • Provision of written informed consent for study participation and scheduled follow-up assessments
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Elazig Fethi Sekin City Hospital Coordinator of this site? Confirm its status | Elâzığ | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.